Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis ...

Medically reviewed by Casey Gallagher, MDAtopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with ...

Eczema, or atopic dermatitis, is a skin condition involving inflammation that leads to cracked, dry, itchy skin. Eucrisa and other PDE4 inhibitors work by slowing and stopping the action of an ...

Red, itchy, and scaly skin from atopic dermatitis and eczema can be uncomfortable, confusing, and all too familiar.

Learn about disparities that exist in atopic dermatitis research and care, including why diverse skin tone representation is important in eczema clinical trials.

Roflumilast is differentiated from Eucrisa in that efficacy appears superior and stinging or burning has not been commonly reported. Roflumilast in Atopic Dermatitis ...

Brian Keegan, MD, PhD, and Michael Cameron, MD, FAAD, describe treatment options for patients with atopic dermatitis.

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

When someone has atopic dermatitis, the barrier is “leaky,” said Dr. Joy Wan, an assistant professor of dermatology at Johns Hopkins University.

JAK inhibitors are the latest class of drugs that treat atopic dermatitis (eczema). Learn more about how they work and potential side effects.

The panelists highlight the treatment nature of ruxolitinib, a JAK inhibitor used to treat atopic dermatitis.

NEW ORLEANS -- A novel lower-concentration topical formulation of the PDE4 inhibitor roflumilast produced rapid improvement in mild to moderate atopic dermatitis (AD) in children and adults, two ...